Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Menghis Bairu"'
Autor:
Reisa A. Sperling, Ron Keren, Gerald Crans, C H van Dyck, Susan Abushakra, Aleksandra Pastrak, G. Quinn, Jesse M. Cedarbaum, Menghis Bairu, Chito Hernandez, Earvin Liang, Pierre N. Tariot, Sid Gilman, Anton P. Porsteinsson, Stephen Salloway, Douglas L. Arnold
Publikováno v:
Neurology. 77:1253-1262
Objective: This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid anti-aggregation agent) in mild to moderate Alzheimer disease (AD). Methods: A total
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9f00614a54de9d7fd89bfcec94ecba3
https://doi.org/10.1212/wnl.0b013e3182309fa5
https://doi.org/10.1212/wnl.0b013e3182309fa5
Autor:
Menghis Bairu, Michael Weiner
Global Clinical Trials for Alzheimer's Disease is a handy one-stop reference for researchers and physicians planning and conducting global clinical trials in this area. This book addresses important considerations that may arise during the successful
Autor:
Menghis Bairu
Publikováno v:
Journal of Commercial Biotechnology. 21
Whether it’s willful counterfeiting, sloppy manufacturing processes, or neglectful handing of drugs in the global supply chain, recent studies suggest the problem of weakened, adulterated, and fake drugs is a growing global issue with deadly c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19e379712e9e5fb24f9b49bc614f5d93
https://doi.org/10.5912/jcb712
https://doi.org/10.5912/jcb712
Publikováno v:
Alzheimer's & Dementia. 10
Background: In a 78-week study in Mild to Moderate AD patients (Study AD201, Salloway et al., Neurology, 2011), oral ELND005 (scyllo-inositol, a myo-inositol stereoisomer) led to beneficial trends on agitation/aggression (Abushakra et al. CTAD 2012),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c51996de26e67eccb14cb7a32b9a0888
https://doi.org/10.1016/j.jalz.2014.05.1686
https://doi.org/10.1016/j.jalz.2014.05.1686
Publikováno v:
Alzheimer's & Dementia. 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b002b11805c206d491d9acb1aeb5919
https://doi.org/10.1016/j.jalz.2014.05.1500
https://doi.org/10.1016/j.jalz.2014.05.1500
Autor:
Patrick Kesslak, Matthias Kurth, Menghis Bairu, Constantine G. Lyketsos, Frank Fan, David Miller, Susan Abushakra
Publikováno v:
Alzheimer's & Dementia. 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d978739af3d8206e1d8d04a2d57ad3e
https://doi.org/10.1016/j.jalz.2014.05.634
https://doi.org/10.1016/j.jalz.2014.05.634
Publikováno v:
Alzheimer's & Dementia. 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcb8e9919a46dd072d08461e60b8becb
https://doi.org/10.1016/j.jalz.2014.05.618
https://doi.org/10.1016/j.jalz.2014.05.618
Autor:
Ricardo F. Allegri, H. Michael Arrighi, Pablo M. Bagnati, Menghis Bairu, Sonia Brucki, Tal Burt, Lorne Cheeseman, Richard Chin, Debbie N. Cote, Jeffrey Cummings, Stephanie Danandjaja, P. Murali Doraiswamy, Murat Emre, James (Dachao) Fan, Yoko Fujimoto, Michel Grothe, Ibrahim Hakan Gürvit, Spencer Guthrie, Harald Hampel, Lynne Hughes, Michael Hüll, Hilal İlbars, Takeshi Iwatsubo, Roy W. Jones, Nadina C. Jose, Amir Kalali, Seong Yoon Kim, Miia Kivipelto, Bernd J. Krause, Jens Kurth, Huafang Li, Francesca Mangialasche, Hans J. Möbius, Ricardo Nitrini, Tiia Ngandu, Muriel O’Byrne, Peter Schüler, Klaudius Siegfried, Sidney A. Spector, Stefan Teipel, Yağiz Üresin, Michael Weiner, Jing Yin, Xue (Kate) Zhong
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ddf95cb08be205d45de9a3c12a30420
https://doi.org/10.1016/b978-0-12-411464-7.00027-4
https://doi.org/10.1016/b978-0-12-411464-7.00027-4
Autor:
Muriel O’ Byrne, Menghis Bairu
Data from clinical trials in emerging markets are becoming a standard component of the regulatory package being provided to support pharmaceutical marketing authorizations including the FDA New Drug Application (NDA) and the EMA Marketing Authorizati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82e4abd0678f51f8093dcd1f9aa83306
https://doi.org/10.1016/b978-0-12-411464-7.00008-0
https://doi.org/10.1016/b978-0-12-411464-7.00008-0